QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:KDMN

Kadmon Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$9.50
0.00 (0.00%)
(As of 11/9/2021)
Add
Compare
Today's Range
$9.50
$9.50
50-Day Range
$8.54
$9.50
52-Week Range
$3.19
$9.50
Volume
1,052 shs
Average Volume
5.11 million shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.


Kadmon logo

About Kadmon

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Headlines

Sanofi completes acquisition of Kadmon - Yahoo Finance
November 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KDMN
Employees
127
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.29 million
Book Value
$0.42 per share

Profitability

Net Income
$-108.91 million
Net Margins
-747.49%
Pretax Margin
-745.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
171,095,000
Market Cap
$1.70 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/18/2022
Next Earnings (Estimated)
3/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

1168th out of 1,414 stocks

Pharmaceutical Preparations Industry

563rd out of 682 stocks

Analyst Opinion: 2.2Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Kadmon (NASDAQ:KDMN) Frequently Asked Questions

Is Kadmon a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Kadmon stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDMN, but not buy additional shares or sell existing shares.
View analyst ratings for Kadmon
or view top-rated stocks.

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Kadmon
.

How were Kadmon's earnings last quarter?

Kadmon Holdings, Inc. (NASDAQ:KDMN) posted its earnings results on Thursday, November, 4th. The company reported ($0.20) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.20). The business earned $14.71 million during the quarter, compared to analyst estimates of $0.42 million. Kadmon had a negative net margin of 747.49% and a negative trailing twelve-month return on equity of 1,167.37%.
View Kadmon's earnings history
.

What price target have analysts set for KDMN?

6 brokerages have issued 1 year target prices for Kadmon's stock. Their forecasts range from $9.00 to $20.00. On average, they expect Kadmon's stock price to reach $11.25 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Kadmon
or view top-rated stocks among Wall Street analysts.

Who are Kadmon's key executives?

Kadmon's management team includes the following people:
  • Harlan W. Waksal, President, Chief Executive Officer & Director
  • Steven Meehan, Chief Financial Officer & Executive Vice President
  • John L. Ryan, Executive Medical Director & Executive VP
  • Gregory S. Moss, Secretary, Chief Compliance Officer & EVP
  • Haya Taitel, Chief Commercial Officer

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the NASDAQ under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%). Company insiders that own Kadmon stock include Cynthia Schwalm and Harlan Waksal.
View institutional ownership trends for Kadmon
.

Which institutional investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Kadmon
or view top insider-selling stocks.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $9.50.

How much money does Kadmon make?

Kadmon has a market capitalization of $1.70 billion and generates $8.29 million in revenue each year. The company earns $-108.91 million in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Kadmon have?

Kadmon employs 127 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is www.kadmon.com.

Where are Kadmon's headquarters?

Kadmon is headquartered at 450 East 29th Street, New York NY, 10016.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at (833) 900-5366, via email at [email protected], or via fax at 646-666-7978.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.